Skip to content

Released Mar 15, 2017, after the close

10-K filed Mar 15, 2017, 74 days after period end · 0001390478-17-000020

Q4 2016 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income$352.00KderivedN/M vs Q4 2015N/M vs Q3 2016
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$8,744,000N/M
Operating Cash Flowderived$25,065,000N/M
Free Cash Flowderived$25,065,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2016derived from reported figuresQ4 2015derived from reported figuresQ4 2014derived from reported figuresQ4 2013
Revenue——$3.20M$1.44M
Net Income$352.00K-$19.68M-$7.96M-$5.52M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR